The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Impact of p16 status on the results of the phase III cetuximab (cet)/radiotherapy (RT).
David Ira Rosenthal
Honoraria - Bristol-Myers Squibb; ImClone Systems
Research Funding - Merck Serono
Paul M. Harari
No relevant relationships to disclose
Jordi Giralt
No relevant relationships to disclose
Diana Bell
No relevant relationships to disclose
David Raben
No relevant relationships to disclose
Joyce Liu
Employment or Leadership Position - Merck Serono
Jeltje Schulten
Employment or Leadership Position - Merck KGaA
K. Kian Ang
No relevant relationships to disclose
James A. Bonner
Consultant or Advisory Role - Bristol-Myers Squibb; Lilly
Honoraria - Bristol-Myers Squibb; Lilly
Research Funding - Bristol-Myers Squibb